Lallemand Health Solutions is proud to announce that Cerebiome® as been shortlisted for the 2025 NutraIngredients Awards in two of the 16 categories. Read

Lallemand Health Solutions is proud to announce the latest findings from a comprehensive study on Cerebiome®. This innovative formula has shown significant benefits for occasional stress, sleep quality, and skin appearance. Read

The Rosell® Institute for Microbiome and Probiotics (RIMAP) by Lallemand has released a new pre-clinical study on their probiotic formulas Cerebiome® and Lacidofil®. The results of this study emphasize the modes of action of probiotics in the gut-brain axis by modulating sleep patterns, depression-like behaviors, and related biomarkers. Read

Frost & Sullivan identifies Lallemand’s Cerebiome® as the world’s most proven psychobiotic. Read

A new post-hoc analysis confirmed in humans that CEREBIOME® can increase significantly BDNF serum levels as observed several years ago in preclinical models. These new results bring more understanding about the potential modes of action of CEREBIOME® on the gut-brain axis, especially on depressive population. Read

Read

Ms. Wallace’s presentation “Bridging the Gap between Nutrition and Psychiatry Using Probiotics” examines the effects of probiotics supplements on symptoms of depression employing a combination of Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175, developed by Lallemand Health Solutions. Read

“Probiotiques Détente” (프로바이오티끄 디땅트), is produced by Lallemand Health Solutions and will be exported to Korea for the first time in March. Read

Probiotic combination of L. helveticus Rosell®-52 and B. longum Rosell®-175, first to be recognized for its specific benefits in stressed healthy adults by ANVISA in brazil Read